Screener
Ligand Pharmaceuticals LGND Proceeds from financial royalty assets
Proceeds from financial royalty assets at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:ProceedsFromFinancialRoyaltyAssets.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's proceeds from financial royalty assets?
- Ligand Pharmaceuticals (LGND) reported proceeds from financial royalty assets of $2.52M in Q2 2026.
- How has Ligand Pharmaceuticals's proceeds from financial royalty assets changed year-over-year?
- Ligand Pharmaceuticals's proceeds from financial royalty assets increased by 24.2% year-over-year, from $2.03M to $2.52M.
- What is the long-term trend for Ligand Pharmaceuticals's proceeds from financial royalty assets?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's proceeds from financial royalty assets has grown at a 381.4% compound annual growth rate (CAGR), from $92K to $10.26M.
- What does proceeds from financial royalty assets mean?
- Proceeds from financial royalty assets as reported by Ligand Pharmaceuticals Inc..
Ask your AI about Ligand Pharmaceuticals's proceeds from financial royalty assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude